

## Press Release

**Nicole Meier**  
Group Communications

Fresenius SE & Co. KGaA  
Else-Kröner-Straße 1  
61352 Bad Homburg  
Deutschland  
T +49 6172 686 2394  
nicole.meier@fresenius.com  
www.fresenius.com

June 8, 2026

### **Fresenius announces European launch of Pedismof® range**

***New ready-to-use three-chamber bag parenteral nutrition solution strengthens Fresenius' global clinical nutrition portfolio and reflect its commitment to patient-centric innovation***

Fresenius, a global healthcare company, today announced the European launch of the Pedismof® range, a new ready-to-use three-chamber bag for pediatric parenteral nutrition. Developed by Fresenius Kabi, the introduction marks an important milestone within the clinical nutrition portfolio and aligns with the Company's #FutureFresenius strategy to foster patient-centric innovation, simplify care, and support patient access to essential therapies.

The range offers age-specific formulations for preterm and term neonates, infants, children, and adolescents, supporting standardized pediatric parenteral nutrition. It is the third product launch this year in the company's clinical nutrition branch. The three-chamber bag combines glucose, amino acids with a balanced profile, and the lipid emulsion SMOFlipid®, which contains fish oil and omega-3 fatty acids. The formulation has been developed in line with established European pediatric nutrition guidelines<sup>1</sup> and is available in multiple volumes to meet the nutritional requirements of most patients.

"The Pedismof® range is an example of how our clinical nutrition portfolio continues to evolve to address specific clinical and patient needs," said Dr. Marc-Alexander Mahl, President Pharma, Nutrition and Sustainability at Fresenius Kabi. "With

age-appropriate formulations and a ready-to-use design, we aim to support healthcare professionals in the delivery of neonatal and pediatric parenteral nutrition within established clinical frameworks.”

Just a few days ago – on June 2<sup>nd</sup>, Fresenius opened an Innovation Center in Germany focused specifically on clinical nutrition. The new center will bring approximately 100 experts from multiple disciplines under one roof, fostering collaboration and speed to continuously develop new products.

This launch is a further proof point of the company’s current strategy phase Rejuvenate by strengthening Fresenius’ clinical nutrition portfolio and underscores the Company’s focus on scalable, system-relevant therapies that contribute to long-term patient access and differentiated health outcomes.

*Availability of Pedismof® range may vary by country and are subject to local regulatory approvals.*

<sup>1</sup>Van Goudoever JB et al. *Clin Nutr.* 2018;37(6 Pt B):2315-2323. Lapillonne A et al. *Clin Nutr.* 2018;37(6 Pt B):2324-2336. Joosten K et al. *Clin Nutr.* 2018;37(6 Pt B):2309-2314. Mesotten D et al. *Clin Nutr.* 2018;37(6 Pt B):2337-2343. Mihatsch W et al. *Clin Nutr.* 2018;37(6 Pt B):2360-2365. Jochum F et al. *Clin Nutr.* 2018;37(6 Pt B):2344-2353.

# # #

Fresenius (XFRA: FRE, OTCQX: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, clinical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually. With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.

For more information, visit [www.fresenius.com](http://www.fresenius.com) and follow Fresenius on [LinkedIn](#).

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA  
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852  
Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE  
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673  
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser  
Chairman of the Supervisory Board: Wolfgang Kirsch